Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY - - Agreement for CASGEVY in transfusion-dependent beta thalassemia (TDT) was previously reached ...

CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas ...

A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Britain's MHRA medical regulator in 2023 became the first in the world to approve the therapy, which uses the gene-editing tool CRISPR ... NHS in August to treat beta thalassemia, another rare ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

As its name suggests, this is a commercial-stage developer of gene therapies that use CRISPR/Cas9 technology ... Casgevy treatment allows sickle cell and beta-thalassemia patients to produce ...

As the company leverages its proprietary CRISPR/Cas9 platform ... dependent β-thalassemia (TDT). The company has reported progress in activating authorized treatment centers (ATCs) and initiating ...